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AbstrACt
Introduction The STOPPIT-2 study aims to determine the 
clinical utility of the Arabin cervical pessary in preventing 
preterm birth in women with a twin pregnancy and a 
short cervix, about which there is current uncertainty. 
STOPPIT-2 will resolve uncertainty around effectiveness 
for women with a twin pregnancy and a cervical length 
of 35 mm or less, define adverse effects, ascertain 
acceptability and estimate National Health Service costs 
and savings.
Methods STOPPIT-2 is a pragmatic multicentre open-
label randomised controlled trial. Consenting women with 
twin pregnancy will have an transvaginal ultrasound scan 
of their cervical length performed between 18+0 and 
20+6 weeks’ gestation by an accredited practitioner: 
women with a cervical length of ≤35 mm will be eligible 
for inclusion in the treatment phase of the study. The 
intervention by the insertion of the Arabin cervical 
pessary will be compared with standard treatment 
(no pessary). The primary outcomes are (obstetric) 
spontaneous onset of labour for the mother leading to 
delivery before 34 weeks’ gestation and (neonatal) a 
composite of specific adverse outcomes or death occurring 
up to the end of the first 4 weeks after the estimated date 
of delivery to either or both babies. We plan to recruit 500 
women in the treatment phase of the study. Assuming a 
treatment effect of 0.6, and background rates of 35% and 
18%, respectively, for each of the primary outcomes, our 
study has 85% power to detect a difference between the 
intervention and the control groups.
Analysis Data will be analysed on the intention-to-treat 
principle.
Ethics STOPPIT-2 was approved by the South East 
Scotland Ethics Committee 02 on 29 August 2014, 
reference number 14/SS/1031 IRAS ID 159610.
Dissemination Peer reviewed journals, presentations at 
national and international scientific meetings.
trial registration number ISRCTN98835694 and 
NCT02235181.
IntroDuCtIon  
Preterm birth is common in twin pregnancy. 
The rate of twinning itself is increasing. Twin-
ning is associated with significant death or 
serious morbidity for the babies, but there 
are no effective treatments. In 2010, 52.7% of 
multiple births were preterm, and there is a 
clear health need for prevention of preterm 
birth in twins. This excess of prematurity 
(compared with singletons) leads to neonatal 
and infant mortality rates of 14.2 and 18.8 
per 1000 live births, respectively (over five-
fold that of singletons). Progesterone appears 
ineffective in preventing preterm birth in 
twins,1 and cerclage appears harmful.2 Prema-
turity is thought to account for over 70% of 
twin neonatal deaths and adversely affects 
fetal survivors, with increased risks of future 
respiratory problems, motor and sensory 
impairment, learning difficulties and social 
and behavioural difficulties.
The costs to the National Health Service 
(NHS) of prematurity in twins are consider-
able. Twins alone account for over 20% of 
neonatal unit cot stays, a significant excess given 
they comprise only 2% of all births. Together, 
the complications of preterm birth result in 
strengths and limitations of this study
 ► Randomised multicentre trial.
 ► Cervical length measured by accredited individuals.
 ► Prespecified cervical length threshold for 
randomisation.
 ► Larger sample size than previously studied.
 ► Inability to blind women or caregivers to treatment 
allocation.
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an estimated annual cost of £2.946 billion to the public 
purse in England and Wales (2006 prices).3 Twins make a 
major contribution to this. There is a clear expressed need 
for innovative interventions to reduce preterm birth in 
both high-income and low-income countries.4 5 The 2011 
National Institute for Health and Care Excellence (NICE) 
Multiple Pregnancy Guideline Group noted that bed rest 
at home or in hospital, progesterone, cervical cerclage and 
oral tocolytics are all ineffective at preventing preterm birth 
in twins, concluding that alternative effective interventions 
are urgently required. The guideline predated the publica-
tion of studies on pessary to prevent preterm birth in twins, 
and there was no attempt to evaluate effectiveness. The 
Cochrane review on ‘cervical pessary for preventing preterm 
birth’6 identified only one randomised trial (in singletons) 
that ‘showed the beneficial effect of the cervical pessary in 
preventing preterm birth’ and called for randomised trials 
to be performed in multiple pregnancy.6
Four randomised trials have reported efficacy of cervical 
pessaries to prevent preterm birth in twins. A summary 
forest plot on the efficacy of the pessary to prevent preterm 
birth (using the entire population randomised each study) 
is shown in the Figure 1. The first trial to be published was 
the ProTwin study, which randomised 813 women with twin 
pregnancy to treatment with an Arabin pessary (inserted 
between 16 and 20 weeks’ gestation) or to standard treat-
ment.7 Although the pessary did not reduce preterm birth 
or the primary neonatal composite outcome overall, both 
of these events were significantly reduced in the prespeci-
fied subgroup of women with a cervical length less than the 
25th centile (n=143) with a relative risk (RR) (95% CI) of 
preterm birth before 32 weeks of 0.49 (95% CI 0.24 to 0.97) 
and RR (95% CI) of composite neonatal outcome of 0.42 
(95% CI 0.19 to 0.91). A subsequent randomised study of 
1180 unselected women showed no difference in the rate 
of the primary outcome of spontaneous birth <34 weeks 
(13.6% vs 12.9%; relative risk 1.054, 95% CI 0.787 to 1.413; 
p=0.722).8 A preplanned subgroup analysis of 214 women 
with a cervical length of ≤25 mm also showed no benefit 
of the pessary (HR 1.256; 95% CI 0.760 to 2.074; p=0.374). 
These data contrast with a smaller study published the 
same year, showing that, in women with a cervical length 
of ≤25 mm, spontaneous preterm birth was less common 
in the pessary group 11/68 (16.2%) compared with the 
expectant management group (26/66 (39.4%)).9 Lastly, the 
Prevention of preterm birth with pessary in twins (PoPPT) 
study of women with twin pregnancy and a cervical length 
≤30 mm at 18+0 to 27+6 weeks' gestation randomised 46 
women and found no difference in the primary outcome 
of preterm birth <34 weeks (39% vs 35%; relative risk, 1.13 
(95% CI 0.53 to 2.40).10
Taken together, these data suggest that the cervical 
pessary does not work in unselected women but may work 
in women with a short cervix (at higher risk of preterm 
birth); consequently, STOPPIT-2 will test the efficacy of 
the Arabin pessary in women with a short cervix. A cervical 
length threshold for recruitment of less than or equal to 
the 30th centile was chosen to maximise the number of 
women who could benefit. When planning the trial, it was 
thought that the 30th centile for cervical length would 
equate to a cervix of ≤30 mm in length, based on a large 
UK study.11 However, a meta-analysis published in the 
early phases of the pilot for STOPPIT-2,12 and data from 
the first 20 women in STOPPIT-2 itself, suggested that the 
30th centile of cervical length in twins at 18–21 weeks’ 
gestation is 35 mm. A cervical length threshold of ≤35 mm 
(which we assume to be the 30th centile) was therefore 
used for eligibility. The quality control measures of the 
Fetal Medicine Foundation (http://www. fetalmedicine. 
com), or the Perinatal Quality Foundation (https:// clear. 
perinatalquality. org), are employed to ensure validity of 
cervical length measurements.
Research priorities identified by NICE include 
randomised trials to determine ‘[effective interventions] 
in preventing spontaneous preterm birth in women with 
twin[s], especially in those at high risk of preterm birth’. 
Additionally, the Preterm Birth Clinical Study Group of 
the Royal College of Obstetricians and Gynaecologists 
(RCOG) identified ‘Efficacy of the Arabin pessary’ among 
its top five research priorities. We are aware of several 
other studies in active or planned recruitment comparing 
a cervical pessary with standard care for prevention 
of preterm birth or its consequences in women with a 
preterm birth including NCT03418311 (planned n=672), 
NCT03058536 (planned n=312), ACTRN12616000875404 
(planned n=140), NCT02708264 (planned n=242), 
NCT02350231 (planned n=100) and NCT01334489 
(planned n=352).
After publication of STOPPIT-2 results, we plan to collab-
orate in subsequent individual patient data meta-analyses 
Figure 1 Forest plot of randomised trials to determine the efficacy of a cervical pessary to prevent preterm birth (as defined in 
each individual study) in twin pregnancy.  
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and update the economic decision model in light of new 
evidence. If the cervical pessary is effective in reducing 
preterm birth in twin pregnancy, it could make a major 
contribution to human health and ensure a more effi-
cient allocation of resources in the UK NHS. However, we 
need to determine whether it is effective (and safe), since 
the evidence to date is not strong or robust enough to 
support its adoption as a first-line intervention.
MEthoDs
Design
STOPPIT-2 is a multicentre open-label randomised 
controlled trial of the Arabin pessary (CE marked device) 
versus standard treatment in women with twin pregnancy 
recruited from NHS antenatal clinics. The study is in two 
phases: a screening phase, in which women with a short 
cervix (cervical length of ≤35 mm) are identified, and a 
treatment phase, in which women with a short cervix will 
be randomised to either treatment with Arabin pessary or 
standard treatment. An internal pilot will be performed 
to assess recruitment rates and to determine feasibility.
objectives
Primary objective
The primary objective of this study is to test the hypoth-
esis that the Arabin cervical pessary reduces spontaneous 
preterm birth in women with a twin pregnancy and a short 
cervix (≤35 mm), reducing adverse neonatal outcomes 
and healthcare costs. We will also address the hypoth-
esis that the pessary is acceptable to pregnant women. 
Subgroup analyses will determine effectiveness in women 
with a cervical length ≤25 mm and in women with a dicho-
rionic pregnancy.
Secondary objectives
The secondary objectives are to confirm (using the entire 
cohort of women undergoing cervical length scanning) 
the profile of cervical length measurements in women 
with twin pregnancy in the UK and the positive and nega-
tive likelihood ratios of a variety of cervical length thresh-
olds to determine spontaneous preterm birth before 34 
weeks’ gestation.
randomisation
Randomisation to Arabin pessary or standard treatment 
is performed by the central randomisation facility at 
the study data centre using a web portal. The allocation 
sequence will be generated by computer. Participants will 
be assigned a unique study identifier, and staff will be 
required to enter minimal patient details prior to rando-
misation. Randomisation will be minimised with a random 
element rather than stratified given the properties of 
minimisation in ensuring comparability between the 
groups. Minimisation variables include booking hospital, 
cervical length and chorionicity (mono or dichorionic) 
but are not limited to these. The study is open (ie, not 
masked), so that both the participant and the investigator 
will know which treatment has been allocated. The inves-
tigator will inform the woman of treatment allocation 
after randomisation.
Population
We will recruit pregnant women who meet the study eligi-
bility criteria and who are booked for delivery at one of 
the participating sites. Case notes will be reviewed by the 
local clinical or research teams prior to recruitment. We 
anticipate that all eligible women expecting twins and who 
are attending for antenatal care in each of the sites will 
be invited to participate. Eligible women will normally be 
informed of the study at routine antenatal appointments. 
The following inclusion and exclusion criteria will apply.
Inclusion criteria (all must apply):
 ► Presenting with twin pregnancy (monochorionic or 
dichorionic).
 ► Gestation established by scan at ≤16 weeks according 
to NICE guidelines.
 ► Aged 16 years or older.
 ► Wishing to participate in both the screening and 
randomisation phase of the study.
 ► Known chorionicity (as defined by first trimester 
ultrasound screening).
Exclusion criteria – screening phase (none must apply):
 ► Unable to give written informed consent.
 ► Known significant congenital structural or chromo-
somal fetal anomaly at the time of inclusion.
 ► Existing or planned cervical cerclage in the current 
pregnancy.
 ► Existing or planned (prior to 20+6 weeks’ gestation) 
treatment for twin to twin transfusion syndrome in 
the current pregnancy.
 ► Suspected or proven rupture of the fetal membranes 
at the time of recruitment.
 ► Bulging fetal membranes at the time of recruitment.
 ► Singleton pregnancy or higher order multiple preg-
nancies and/or women who have had any fetal death 
(ie, fetal heart and previously detected) in the index 
pregnancy (prior to randomisation).
 ► Known sensitivity, contraindication or intolerance to 
silicone.
 ► Involved in a clinical trial of an investigational medic-
inal product, phase 1 study or investigating a treat-
ment for the prevention of preterm birth.
 ► Monochorionic monoamniotic pregnancy.
 ► Heavy bleeding due to a low-lying placenta prior to 
randomisation.
Inclusion criteria – screening phase:
 ► Cervical length ≤35 mm at 18+0–20+6 weeks’ gesta-
tion confirmed by an accredited clinician.
Exclusion criteria – treatment phase (none must apply):
 ► Cervical length >35 mm at 18+0–20+6 weeks’ gestation.
 ► Cervical length not measured at 18+0–20+6 weeks’ 
gestation.
 ► Bulging fetal membranes at the time of pessary 
insertion.
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 ► Suspected or proven rupture of the fetal membranes 
at the time of pessary insertion.
To assess eligibility for the treatment phase, all women 
who fulfil the inclusion criteria for the screening phase 
will undergo ultrasound measurement of cervical length 
between 18+0 and 20+6 weeks’ gestation by an accredited 
operator (see later). If convenient, cervical length meas-
urement may be done at the time of the routine fetal 
anomaly scan. In centres where cervical length measure-
ments are part of routine clinical care women may be 
consented after the cervical length and will not be asked 
to have a further TV scan, provided:
 ► The transvaginal scan measurement was taken by 
an accredited operator (completed cervical length 
education and review (CLEAR, USA) or Fetal Medi-
cine Foundation cervical length training) and is dele-
gated by the principal investigator (PI).
 ► The TV scan was conducted between 18+0 and 20+6 
weeks’ gestation.
 ► The woman is eligible (as per the above inclusion/
exclusion criteria) and the pregnancy is not ≥21 
weeks’ gestation.
Images of the cervical length measurements will be 
anonymised and uploaded to the electronic case report 
form (eCRF).
Women with a cervical length of ≤35 mm will continue 
to the treatment phase, following verbal reconfirmation 
of intent to participate and randomised to either the 
intervention or the comparator group as described below.
Enrolment and adherence of participating centres
We will recruit from UK NHS and European hospitals. 
Sufficient centres will be involved to ensure that our 
planned sample size is achieved. Regular meetings will 
be held with clinicians and research staff from recruiting 
centres to maintain study enthusiasm and to achieve our 
planned sample size.
Intervention
The intervention is the Arabin pessary, inserted through 
the vagina and around the cervix between 18+0 and 20+6 
weeks’ gestation and given in addition to standard care. 
Video instructions for pessary insertion are available 
on the Arabin website (https:// dr- arabin. de/ produkt/ 
arabin- cerclage- pessary- perforated/? lang= en). There are 
no prohibited cotreatments. A trained member of the 
local research team will insert the pessary.
Comparator
The comparator is standard care. There are no prohib-
ited cotreatments.
outcomes (women recruited to screening and treatment 
phase)
There are two primary outcomes: an obstetric and a 
neonatal primary outcome.
 ► Obstetric primary outcome: all births before 34+0 
weeks following the spontaneous onset of labour. 
Preterm prelabour rupture of membranes <34 weeks 
with or without contractions will also be included in 
this definition of spontaneous onset of labour.13 Iatro-
genic delivery due to maternal or fetal conditions will 
not be considered to fulfil the criteria for the primary 
outcome.
 ► Neonatal primary outcome: the primary neonatal 
outcome is a composite of adverse outcomes including 
stillbirth or neonatal death, periventricular leukoma-
lacia, early respiratory morbidity (defined as any need 
for supplemental oxygen >30%, continuous positive 
airway pressure (CPAP) or intratracheal ventilation or 
surfactant replacement therapy within the first week 
of life), intraventricular haemorrhage, necrotising 
enterocolitis and proven sepsis all measured up to 28 
days after the expected date of delivery.
Obstetric
Key outcomes
 ► Mean gestation at delivery.
 ► Adverse events: infection and cervical trauma.
 ► Incidence of all births before 37+0 weeks’ gestation.
 ► Acceptability of the pessary as determined by partici-
pant questionnaire.
 ► Experience of pessary removal.
Other outcomes
 ► Incidence of all births before each of 28+0, 32+0, and 
34+0 weeks’ gestation.
 ► Preterm birth before 34 weeks’ gestation preceded by 
preterm premature membrane rupture.
 ► Incidence of all births before 28, 32, 34 and 37 weeks 
preceded by the spontaneous onset of labour.
 ► Method of delivery (in three categories: sponta-
neous vaginal delivery or vaginal breech, forceps or 
ventouse and caesarean section).
 ► Duration of labour overall and of each of the first and 
second stages of labour.
 ► Duration of stay in hospital.
 ► Other adverse events including haemorrhage, tachy-
cardia, vaginal injury and other trauma.
 ► Serious maternal adverse events up to 28 days after 
discharge from the hospital.
Key neonatal secondary outcomes
 ► Incidence of each of the individual components of 
the primary neonatal outcome.
 ► Median weight (g) of the newborn at birth.
 ► Death of live-born babies within the first 28 days after 
birth.
 ► Discrete episodes of bloodstream or central nervous 
system (CNS) infection (positive blood or cerebro 
spinal fluid (CSF) culture).
 ► Within first 72 hours.
 ► Between 72 hours and discharge.
Other neonatal outcomes
 ► Birth weight centile (for gestation) within 4 weeks 
after expected date of delivery.
 ► Death of live-born babies within the first 28 days after 
estimated date of delivery (EDD).
 ► Cord pH.
 ► Apgar score at 1 min and 5 min.
 o
n
 18 January 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026430 on 6 December 2018. Downloaded from 
5Norman JE, et al. BMJ Open 2018;8:e026430. doi:10.1136/bmjopen-2018-026430
Open access
 ► Need for resuscitation.
 ► Need for surfactant administration.
 ► Bronchopulmonary dysplasia.
 ► Retinopathy of prematurity (stage 1 or more).
 ► Retinopathy of prematurity requiring surgery (laser 
or cryotherapy).
 ► Necrotising enterocolitis (medical or surgical treat-
ment of confirmed cases).
 ► Twin to twin transfusion (Quintero stage 1 or more).
 ► Days of respiratory support (either mechanical venti-
lation or CPAP).
 ► Days of oxygen therapy.
 ► Daily level of care.
 ► Seizures requiring therapy.
 ► Hyperbilirubinaemia requiring exchange transfusion.
 ► Periventricular leukomalacia/echogenicity.
Other outcomes include:
 ► Acceptability and experience of the pessary as deter-
mined by participant questionnaire issued at 36 
weeks’ gestation.
 ► The joint distribution of the cumulative hospital costs 
and the primary clinical outcome.
 ► Cervical length measurements for all participants to 
determine the likelihood ratios for short cervix and 
spontaneous preterm birth.
We will also collect information on use of the following 
therapies to allow sensitivity analyses in future individual 
patient data meta-analyses:
 ► Progestogens (Intramuscular, IM or vaginal) after 16 
weeks’ gestation.
 ► Cervical suture postrandomisation.
 ► Tocolytics.
 ► Steroids.
 ► Magnesium sulfate.
 ► Antibiotics.
 ► Arabin pessary in the screened-only women.
outcomes (women recruited to screening phase only)
For women recruited to the screening phase but who are 
not randomised, we will collect maternal and neonatal 
outcomes as described above. We will not collect informa-
tion on cotreatments (other than those described above), 
adverse events, acceptability or costs.
Criteria for discontinuing intervention
Participation is voluntary. A woman has the right to 
discontinue or withdraw at any time for any reason. The 
investigator also has the ability to discontinue a partici-
pant. The reason and circumstances will be documented 
in the eCRF. Unless a participant asks to completely with-
draw from the study, those who discontinue treatment 
will be asked to continue to participate in study visits to 
facilitate analysis under the intention to treat principle.
If treatment is suspended or stopped due to a serious 
adverse reaction, the local PI will arrange for follow-up 
visits or telephone calls until the event has resolved or 
stabilised or until the study has ended, whichever is 
sooner. In order to avoid bias and/or missing adverse 
events, outcome data will be collected (including data 
from the patient record) and used in the analysis.
We will note whether participants have adhered to the 
treatment assignation. In the intervention arm, we will 
define adherence as women who have a pessary in situ 
at 28 weeks’ gestation (whether it has been out and been 
reinserted during that time). Women who deliver before 
28 weeks will count as adherent if they had their pessary 
until 7 days before delivery. Those in the standard care 
arm will be considered adherent unless they had a pessary 
inserted.
Visits
Study visits will be conducted at approximately 4 weekly 
intervals (plus or minus 1 week) following randomisation 
until 36 weeks, when the pessary will be removed. The 
study visits will be carried out on those randomised to the 
pessary and those undergoing standard treatment. Study 
visits could be face to face or by phone or other means 
of communication, for example, via letter or email. Preg-
nancy and fetal well-being will be reviewed at these visits. 
Additionally, we will collect the following outcomes:
 ► Any pregnancy complications (adverse events) 
including bleeding.
 ► Experience of the pessary during the previous 4 weeks 
(if applicable).
 ► Hospital admissions (serious adverse events) – reasons 
and duration.
Pessary removal
The pessary will be removed at 35+0–36+6 weeks’ gestation. 
The participant will be asked to complete a short ques-
tionnaire about her experience and (if appropriate) of 
having the pessary. For those allocated to pessary treat-
ment, a vaginal examination will be conducted, and the 
pessary will be removed. Information will be collected on 
the ease with which removal was achieved. If the pessary 
is removed before 35 weeks, we will record the indication.
Ancillary and post-trial care
Care of participants in parallel to and beyond the trial 
will be provided within the UK National Health service. 
There will be no no-fault compensation for those who 
suffer harm from trial participation.
Qualitative data
A nested qualitative study involving pregnant women will 
explore their views and experiences of methods of recruit-
ment and the consent process, their understanding and 
expectations of trial participation, including randomisa-
tion and the screening component, and experiences of 
the intervention. We will interview women who:
 ► Consented, were screened but found to have a long 
cervix (up to 10).
 ► Consented, were screened, have a short cervix and 
were randomised and allocated to the control group 
(up to 10).
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 ► Consented, were screened, have a short cervix and 
were randomised and allocated to the treatment 
group (up to 20).
Up to 15 interviews will be conducted with a range of 
healthcare professionals involved in the trial in order to 
explore their views and experiences of the process.
baseline characteristics (screening and treatment phase)
In addition to the outcomes, we will collect the following 
baseline characteristics on all women:
Age
Height
Weight
Cervical length
Current smoking
Current alcohol
Obstetric history: parity, miscarriage
Medical conditions: hypertension, Insulin dependent 
diabetes, respiratory disease, cardiac disease
Neurological disease, skin condition, thrombophilia, 
current pregnancy
Fetal anomaly scan: twin 1, twin 2 (whether performed 
and the result)
Amniocentesis: twin 1, twin 2 (whether performed and 
the result)
Data collection forms are available on the STOPPIT-2 
website at https:// w3. abdn. ac. uk/ hsru/ STOPPIT2/ 
Public/ DownloadPage. aspx.
Consent
Written informed consent will be obtained from all partic-
ipating women. Model information sheet and consent 
forms are available on the study website at https:// w3. 
abdn. ac. uk/ hsru/ STOPPIT2/ Public/ DownloadPage. 
aspx. Women will be given information about the study 
by the investigator team at each study site, invited to 
consider participation and will be given adequate time 
(at least 24 hours) to read the information sheet. If the 
woman waives this opportunity but still wishes to partic-
ipate, consent may be taken after a shorter time. Details 
of the consent process, including the name of the doctor 
confirming eligibility and the member of the study 
team taking consent will be recorded in the woman’s 
notes and in the eCRF. Women undergoing ultrasound 
measurement of the cervix will be asked to complete a 
consent form prior to the procedure, which will cover 
both screening and treatment phases of the study. This 
will minimise inconvenience to the women (reducing the 
number of visits required to the hospital) and minimise 
the time undergoing vaginal examination. We will seek 
permission for future long-term follow-up of the women 
and babies via record linkage into national databases 
(health, social and educational) although such follow-up 
is beyond the scope of the study described here.
Data analysis (screening phase data)
We will use cervical length measurements at baseline 
screening, gestation at delivery, whether delivery was 
preceded by spontaneous onset of labour and/or preterm 
premature membrane rupture to determine positive and 
negative likelihood ratios for spontaneous preterm birth 
before 34 weeks for a variety of cervical length thresholds. 
Women treated with the pessary will be excluded from 
this analysis.
Data analysis (treatment phase data)
The statistical analysis will be according to the intention 
to treat principle; all participants will remain in their 
allocated group for analysis. Statistical significance will 
be at the 5% level with corresponding 95% CIs derived. 
Randomised groups will be described at baseline and 
follow-up using mean (SD), median (IQR) and counts 
(with percentages) where appropriate.
For the primary obstetric and neonatal outcomes, 
logistic regression with a fixed effect for the minimisation 
covariate chorionicity and a random effect for centre will 
be used to obtain the ORs of the treatment effect, along 
with the 95% CI and associated p value. In the case of 
the composite neonatal outcome, the components will 
also be reported individually to show which elements 
are driving the primary outcome. In the case of skewed 
recruitment resulting in small centres, a regional effect 
will be considered in place of a centre effect.
Continuous secondary outcomes will be analysed using 
linear regression, adjusting for chorionicity. Binary cate-
gorical secondary outcomes will be analysed using logistic 
regression as per the primary outcomes.
Secondary outcomes with more than two categories will 
be analysed using multinomial logistic regression.
Analysis of fetal outcomes will allow for clustering 
within twins by fitting mother as a random effect in a 
mixed effects logistic regression model.
We will undertake predefined subgroup analyses of 
the primary outcome by monochorionicity, cervical 
length (≤25 mm and ≤28 mm). In the subgroup analyses, 
statistical significance will be at the 1% level with corre-
sponding 99% CIs.
It is not anticipated that primary outcome data will be 
missing. If data are missing, this is likely to be due to a 
miscarriage, stillbirth, neonatal or maternal death and 
therefore it will not be imputed.
A post hoc comparison will also be performed between 
participants who had membrane rupture and those who 
did not.
A per-protocol analysis (including those in the inter-
vention arm who are adherent, and excluding those in 
the control arm who have a pessary inserted) will also be 
performed.
No formal interim analyses are planned.
The statistical analysis plan is included as online supple-
mentary appendix 1 to this paper.
Data management
The primary source of data arise from medical notes. These 
data are entered directly from source, by study site staff, into 
the eCRF. The eCRF has been developed in accordance 
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with CHaRT software development standards at the Univer-
sity of Aberdeen. Data entry is carried out remotely by 
authorised study personnel. Accuracy of entry and the 
storage of source documentation is the responsibility of site 
study personnel. Validation checks will be set up and run 
in real time on the eCRF. Checks will include missing data, 
out of range values, illogical entries and invalid responses. 
Users will be informed of data issues when the eCRF page 
is saved providing users with the opportunity to correct the 
data immediately, where possible. The eCRF system will 
generate a missing data query for all items not completed 
at the time. Cross-form checks comparing data items across 
different forms will be created, where possible or written as 
reports.
Data analysis (health economic data)
The economic component will consider the joint distribu-
tion of the cumulative hospital costs and the primary clinical 
outcome from the perspective of the UK NHS. Generalised 
linear models will be used to estimate the costs between the 
two treatment groups. The cost estimates and primary clin-
ical outcome will be combined within a cost-effectiveness 
analysis to calculate the incremental cost per preterm birth 
prevented. The length of stay distributions will be valued 
using a per diem unit cost derived from NHS reference 
costs.13 Monetary values will be attached to the labour costs 
for healthcare practitioners associated with each treatment 
pathway using standard NHS pay and price estimates.14 15 
No discounting of hospital costs and clinical outcomes will 
be undertaken for the within-trial economic component. 
Flexible parametric regression models will be used to 
explore the dependency between cost and the primary clin-
ical outcome as well as heterogeneous treatment effects 
within a sensitivity analysis to inform a decision-analytic 
model. A decision model will be developed to estimate the 
longer term resource consequences and health outcomes of 
preterm birth following twin pregnancy. Model parameter 
uncertainty will be addressed using probabilistic sensitivity 
analysis summarised using the cost-effectiveness accept-
ability curve at differing willingness to pay thresholds.
Data analysis (qualitative research)
The nested qualitative interview study will be analysed using 
an inductive cross-sectional thematic approach described 
by Mason.16 This approach involves applying indexing 
coding to the entire data set providing the means to identify 
patterns and themes in the data from each arm of the study. 
The use of qualitative software will also help to facilitate 
a collaborative approach to the analysis thereby ensuring 
consistency and rigour.17 This method has been chosen as 
it will help to identify how women experience all aspects 
of the study in the context of their current pregnancy that 
builds up a descriptive and conceptual interpretation of 
the findings that maintains the integrity of each research 
participant’s accounts. The same analytical approach will 
be taken for the data generated through interviews with 
healthcare professionals.
study monitoring
On site, trial monitoring will not be conducted on 
behalf of the cosponsors. Remote monitoring to verify 
eligibility, consent, staff training and data entry quality 
will be performed. The research involves the use of a 
CE marked device used for its intended purpose. Audits 
may be carried out by individual site R&D departments 
as per the Research Governance Framework; these 
audits are independent of the sponsors.
A trial steering committee (TSC) and a data moni-
toring committee (DMC) will be appointed. The 
membership and charter for each is included in 
online supplementary appendix 2 and supplementary 
appendix 3. The committees will meet not less than 
annually, or more often if issue arises. There are no 
formal stopping rules: the TSC and DMC charters state 
that ‘The TSC, based on recommendations from the 
DMC, may recommend early termination of the trial 
or modification of the study design in the event of a 
clear accumulating data or on the basis of information 
available from other sources or on safety grounds’. 
‘Recommendations to amend the protocol or conduct 
of the study made by the DMC will be considered and 
either accepted or rejected by the TSC. The TSC will be 
responsible for deciding whether to continue or to stop 
the trial based on the DMC recommendations’.
Confidentiality of data
All records such as laboratory specimens, question-
naires and evaluation forms will be identified in a 
manner designed to maintain participant confidenti-
ality. All records will be kept in a secure storage area with 
limited access. Collection of participant identifiers is 
performed only to ensure compliance with governance 
procedures (eg, confirmation of informed consent). 
Paper records with identifying information will be kept 
in a locked cabinet with limited access. Electronic iden-
tifying information will be kept in a separate trial data-
base and will not be revealed as part of routine data 
analysis or in any data sharing exercise. Clinical infor-
mation will not be released without the written permis-
sion of the participant. The investigator and study site 
staff involved with this study will not disclose or use for 
any purpose other than performance of the study, any 
data, record or other unpublished, confidential infor-
mation disclosed to those individuals for the purpose of 
the study. Prior written agreement from the sponsor or 
its designee must be obtained for the disclosure of any 
said confidential information to other parties.
Data protection
All Investigators and study site staff involved with this 
study must comply with the requirements of the Data 
Protection Act 1998 and subsequent General Data 
Protection Regulations 2018 with regard to the collec-
tion, storage, processing and disclosure of personal 
information and will uphold the Act’s core principles. 
Access to collated participant data will be restricted to 
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those clinicians treating the participants, representa-
tives of the sponsor(s) and representatives of regulatory 
authorities. Computers used to collate the data will have 
limited access measures via user names and passwords.
Published results will not contain any personal data 
that could allow identification of individual participants.
sample size calculation
We plan to recruit 2500 women to the SCREENING 
phase and randomise 500 women in the treatment 
phase. We anticipate that around 58 sites (largely UK 
NHS sites) will be involved.
Women with a short cervix are at higher risk of 
preterm birth and may benefit most from pessary treat-
ment. We aim to treat women with a cervical length 
≤35 mm, which we believe to be around the 30th centile. 
Assuming this to be correct, a sample size of 1850 
screened was initially identified to generate 555 eligible 
for randomisation in the treatment phase. However, 
following reanalysis of data (masked to treatment allo-
cation) in September 2017 after 29 months of screening 
(with data on 1214 women screened), we estimated that 
to randomise 550 women, the sample size of screening 
needed to increase to 2500. Although we will encourage 
women to participate in the screening phase only if they 
wish also to participate in the treatment phase, we have 
allowed for a further 10% drop out after screening, so 
that we now aim to randomise 500 women in the treat-
ment phase.
We plan to randomise 500 women (250 in each group). 
We assume a relative risk of the primary obstetric outcome 
(spontaneous preterm labour leading to preterm birth 
before 34 weeks) in the pessary group of 0.6. We believe our 
relative risk reduction is conservative, given a relative risk 
of 0.49 for delivery before 32 weeks7 and 0.47 for delivery 
before 34 weeks (21% vs 42%) (S Liem, personal communi-
cation, 2013) in the ProTwin study. We anticipate that 35% 
of women in the control group will deliver before 34 weeks. 
We believe that this is a conservative estimate, given that 
a systematic review indicated that 34.9% of women with a 
cervical length of 35 mm or less (when scanned at 20 weeks’ 
gestation) will deliver preterm before 32 weeks.12 Assuming 
a baseline rate of 35% and a relative risk of 0.6, a sample 
size of 500 has 94% power to detect a difference at the 5% 
significance level. If the preterm birth rate before 34 weeks 
is only 30%, the power drops to 88%. Both allow for losses 
to follow-up and imperfect compliance.
For the primary neonatal outcome, Liem showed an 
effect size of 0.42 at the child level and an incidence of 24% 
in the control group.7 We have powered our study for a rela-
tive risk of 0.6 for the primary neonatal outcome. Assuming 
prevalence rates as in Liem, our study would have 97% 
power. In practice, our postscreening groups of women 
with cervical length ≤35 mm is probably a lower risk than 
in the Liem group (less than 38 mm), given comparisons of 
the rate of preterm delivery in each of the control groups. 
Hence, if we assume a lower rate of the neonatal primary 
outcome of (say) 18%, we still have 88.4% power to detect 
a relative risk of 0.6 in the Arabin pessary group. Such a 
calculation assumes analysis at the child level is appropriate 
for the neonatal outcome.
For the subgroup of women with cervical length of 
≤25 mm, the anticipated rate of the primary obstetric 
outcome in the control group is 82/159 (51%).11 The study 
has 85% power to detect a relative risk of 0.6 in this group, 
with a sample size of 234 (25 mm was the 14th centile in the 
To et al).
Patient and public involvement (PPI)
The importance of the research question was identified 
by two major groups, both involving PPI.
The first was the NICE guideline on multiple preg-
nancy, published in 2011, which had embedded PPI.
The guideline generated the following research recom-
mendation: ‘What interventions are effective in preventing 
spontaneous preterm birth in women with twin and triplet 
pregnancies, especially in those at high risk of preterm 
birth? The second group was the Clinical Study Group 
from the RCOG, which has extensive lay and patient 
involvement. ‘The use of the Arabin pessary for preventing 
preterm birth’ is one of five research priorities identified in 
late 2012.
There was PPI in the development of the protocol at 
grant submission stage, including in choice of the outcome 
measures. Specifically, the CEO of a charity focusing on 
preterm birth (Jane Denton, Multiple Births Foundation) 
who was a coapplicant on this project was and involved in 
the study design.
Patients and the public are also involved in the TSC for 
this study, which oversaw the conduct of the study: both 
through participation of individual patients and through 
participation of Keith Read from Tamba (The Twins and 
Multiple Births Association) and two individual patients. 
Although PPI were not directly involved in individual 
patient recruitment, they provided helpful comments 
on the patient information sheet used for this purpose. 
PPIs were members of the ethics committee who assessed 
the research burden associated with participating in this 
study.
Individual study participants will be sent a summary of 
study findings, when the main study is published. We also 
make use of our connections with the charities Tommy’s, 
the Multiple Births Foundation and the Twins and Multiple 
Births Association to disseminate information.
Dissemination
A study report will be prepared in accordance with Good 
clinical practice (GCP) guidelines and submitted to the 
funder National institute for health research (NIHR) 
for publication in the NIHR journals library. A summary 
report will be submitted for publication in a peer review 
journal. Data will be used for publication and presentation 
at scientific meetings. Authorship guidelines are attached at 
online supplementary appendix 4.
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Access to data
The chief investigator (JEN) and all study statisticians 
(JN, GM and DC) will have full access to the final dataset 
data during analysis. Access will be provided to any other 
author on request. There are contractual limitations on 
disclosures.
Data deposition
We aim to deposit the data in a shared depository. We do 
not anticipate providing access to the statistical analysis 
code.
Protocol amendments
Version 1 of the STOPPIT 2 protocol dated 22 July 2014 
was approved by the ethics committee on 29 August 
2014. A list of protocol amendments is included in an 
online supplementary appendix 5. It is not anticipated 
that any further substantive amendments will be made, 
other than addition or closure of sites. Protocol amend-
ments are notified to and approved by the sponsor, 
funder and research ethics committee and communi-
cated to investigators after approval. The most recent 
approved version of the protocol is version 4, dated 10 
January 2018. One final amendment of the protocol will 
be submitted to address minor updates made during the 
preparation of this protocol paper.
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